PureTech Health PLC Transaction in Own Shares (0108T)
November 10 2023 - 2:00AM
UK Regulatory
TIDMPRTC
RNS Number : 0108T
PureTech Health PLC
10 November 2023
10 November 2023
PureTech Health plc
Transaction in Own Shares
PureTech Health PLC (the "Company") announces that it has
purchased the following number of its ordinary shares of one pence
each through Jefferies International Limited ("Jefferies"), as part
of its Share Buyback Programme, details of which were announced on
9 May 2022.
Date of purchase: 9 November 2023
Number of ordinary shares purchased: 1,835
Highest price paid per share: 168.60p
Lowest price paid per share: 168.60p
Volume weighted average price paid per
share: 168.60p
PureTech intends to retain the purchased shares in treasury.
Following the above transaction, the Company will have
16,196,707 ordinary shares in treasury and has 273,271,452 ordinary
shares in issue (excluding treasury shares). The total number of
voting rights in the Company is therefore 273,271,452 wh ich may be
used by shareholders in their calculations to determine if they are
required to notify their interest in, or a change to their interest
in, PureTech Health plc under the FCA's Disclosure Guidance and
Transparency Rules.
In accordance with Article 5(1)(b) of Regulation (EU) No
596/2014 (as incorporated into UK domestic law by the European
Union (Withdrawal) Act 2018) (the Market Abuse Regulation),
detailed information about the individual purchases is available
below.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to giving life to new classes of medicine to change the lives of
patients with devastating diseases. The Company has created a broad
and deep pipeline through its experienced research and development
team and its extensive network of scientists, clinicians and
industry leaders that is being advanced both internally and through
its Founded Entities. PureTech's R&D engine has resulted in the
development of 27 therapeutics and therapeutic candidates,
including two (Plenity(R) and EndeavorRx(R)) that have received
both U.S. FDA clearance and European marketing authorization and a
third (KarXT) that has been filed for FDA approval. A number of
these programs are being advanced by PureTech or its Founded
Entities in various indications and stages of clinical development,
including registration enabling studies. All of the underlying
programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and
then advanced by the PureTech team through key validation
points.
For more information, visit www.puretechhealth.com or connect
with us on X, formerly known as Twitter, @puretechh.
Contact:
PureTech
Investor Relations
IR@puretechhealth.com
Individual Transactions
Transaction Transaction Volume Price Platform Transaction Reference
Date Time (GBp) Number
09/11/2023 13:08:35 634 168.6 XLON 00377768603TRLO0.1.1
------------ ------- ------- --------- ----------------------
09/11/2023 13:08:35 71 168.6 XLON 00377768604TRLO0.1.1
------------ ------- ------- --------- ----------------------
09/11/2023 13:08:35 195 168.6 XLON 00377768605TRLO0.1.1
------------ ------- ------- --------- ----------------------
09/11/2023 14:15:47 207 168.6 XLON 00377779945TRLO0.1.1
------------ ------- ------- --------- ----------------------
09/11/2023 14:21:49 243 168.6 XLON 00377781080TRLO0.1.1
------------ ------- ------- --------- ----------------------
09/11/2023 16:00:27 450 168.6 XLON 00377813237TRLO0.1.1
------------ ------- ------- --------- ----------------------
09/11/2023 16:00:27 35 168.6 XLON 00377813238TRLO0.1.1
------------ ------- ------- --------- ----------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
POSFLFFTLFLAIIV
(END) Dow Jones Newswires
November 10, 2023 02:00 ET (07:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024